What's Happening?
Dr. Anne-Claire Amprou, France’s Ambassador for Global Health, has joined the leadership of the World Health Organization (WHO) Intergovernmental Working Group (IGWG) negotiating the Pathogen Access and Benefit-Sharing (PABS) annex of the Pandemic Agreement.
This development comes at a critical juncture, as WHO member states have been unable to reach a consensus on how to share information on dangerous pathogens and the medical products derived from that knowledge since July 2025. Dr. Amprou previously co-chaired the final stages of the broader Pandemic Agreement talks, which successfully achieved consensus. Her appointment is seen as an effort to break the current deadlock in the PABS negotiations, which are essential for the full implementation of the Pandemic Agreement. WHO Director-General Dr. Tedros Adhanom Ghebreyesus emphasized the strong political support for completing the annex, highlighting that its purpose is to protect people globally, as a pathogen threat anywhere can become a threat everywhere. The United Nations General Assembly recently adopted its Political Declaration on pandemic prevention, preparedness, and response, urging the conclusion of the PABS negotiations.
Why It's Important?
The ongoing stalemate in the PABS annex negotiations has significant implications for global health security and future pandemic preparedness. Without an agreed-upon framework for pathogen access and benefit-sharing, the world risks repeating the inequities observed during the COVID-19 pandemic, where access to life-saving tools was unevenly distributed. The International Council of Nurses (ICN) has warned that delays in operationalizing the Pandemic Agreement and its PABS annex could lead to a recurrence of situations where nurses and vulnerable communities in lower-income countries face dangerous delays in accessing vaccines, treatments, and protective equipment. The lack of a clear, workable, and predictable system for sharing pathogen materials and information could hinder rapid research and development efforts by pharmaceutical companies, as highlighted by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). The core issue revolves around ensuring that access and benefit-sharing are treated as inseparable and equally important pillars, preventing a system where access is by design but benefits are by convenience, which could erode trust among countries providing pathogen materials.
What's Next?
The ninth formal meeting of the IGWG is underway, with Dr. Amprou expected to be formally presented for consideration as co-chair. Negotiators are urged to focus on finding solutions, distinguishing between essential and desirable elements, and prioritizing public health. The European Union has proposed various discussion formats, including formal and informal sessions, and smaller group meetings, to facilitate progress. Non-state actors, such as IFPMA, continue to advocate for arrangements that encourage broad participation to ensure the PABS system works effectively and rapidly during future pandemic threats. The outcome of these negotiations will determine the effectiveness of the broader Pandemic Agreement and the world's ability to respond equitably to future health crises. The ICN will also provide input to the UN Special Rapporteur's report on the human rights implications of these delays, further emphasizing the urgency of a resolution.
Beyond the Headlines
The debate over the PABS annex highlights a fundamental tension between national sovereignty and global health equity. Countries providing pathogen materials, particularly those in the Global South, are seeking assurances that they will receive equitable benefits, such as access to vaccines and treatments, in exchange for sharing critical data. This reflects a broader push for multilateralism that ensures no country is left behind in a health crisis. The 'federated model' proposed by the Africa Group, where pathogen materials and data remain under national or regional control with benefit-sharing contracts, underscores the desire for greater control and fair compensation. The success of the PABS annex will not only depend on legal and procedural agreements but also on building trust and demonstrating a genuine commitment to global solidarity, moving beyond a system perceived as charity to one based on mutual responsibility and benefit. The ethical implications of unequal access to life-saving medical advancements during a pandemic are a central theme driving these complex negotiations.
